30 recruiting, 15 active not recruiting, 13 completed, 13 not yet recruiting. 87 Phase 2, 7 Phase 3, 6 Phase 1.
Follow Androgen Antagonists: new trials by email Literature Review of Androgen Antagonists trials Research Report on Androgen Antagonists
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer Antiandrogen Therapy, Biopsy Procedure, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 24 | 2027-02-26 | 2026-11-04 |
| Testosterone-Informed De-Escalation in Metastatic Prostate Cancer (TIDE PC) Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitors (ARPIs) - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 2 | Not yet recruiting | University of Nebraska | 56 | 2026-12-24 | 2026-11-03 |
| RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation - Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 2 | Not yet recruiting | Georgetown University | 108 | 2026-12-01 | 2026-10-06 |
| A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer. ADT plus abiraterone or other ARPIs（apalutamide, enzalutamide, rezvilutamide, darolutamide) - Metastatic Hormone-Sensitive Prostate Cancer | Phase 2 | Not yet recruiting | Anhui Medical University | 40 | 2026-10-01 | 2026-08-31 |
| PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC Stereotactic Body Radiotherapy (SBRT), Darolutamide 600 mg twice daily, Androgen Deprivation Therapy (ADT) - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 2 | Not yet recruiting | West China Hospital | 254 | 2026-09-15 | 2026-09-10 |
| Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone - Prostate Cancer | Phase 2 | Recruiting | University of Nebraska | 140 | 2026-09-01 | 2026-10-19 |
| A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs De-escalation strategy, Continuation of initial Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitor (ARPI) combination therapy at standard doses - Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Not yet recruiting | Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute | 170 | 2026-09-01 | 2026-10-07 |
| Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer Ra223, Darolutamide Oral Tablet, Androgen Deprivation Therapy (ADT) - Metastatic Hormone-Sensitive Prostate Cance | Phase 2 | Not yet recruiting | Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD | 50 | 2026-09-01 | 2026-07-21 |
| Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer Androgen Deprivation Therapy (ADT), Radiotherapy - Prostate Cancer | Phase 2 | Recruiting | NYU Langone Health | 90 | 2026-08-06 | 2026-09-03 |
| Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer Metastasis-directed radiotherapy, Rezvilutamide + ADT, Radical prostatectomy - Oligometastatic Prostate Cancer | Phase 2 | Not yet recruiting | Fudan University | 300 | 2026-05-01 | 2026-03-24 |
| Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer Dapagliflozin (10mg Tab), standard medical care (ADT + NHA) - Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Recruiting | Yung NA | 68 | 2026-05-01 | 2026-10-28 |
| Androgen-responsive POSLUMA-guided Intra-prostatic Boost PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost - Intermediate Risk Prostate Cancer, High Risk Prostate Cancer | Phase 2 | Recruiting | Martin T. King, MD, PhD | 23 | 2026-04-29 | 2026-05-29 |
| Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer Darolutamide, Darolutamide combined with ADT - Prostate Cancer | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 60 | 2026-04-01 | 2026-03-17 |
| PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer Ultrahypofractionated Whole-Pelvis Radiotherapy, SBRT-Based Prostate Radiotherapy (No Boost), Ablative Prostate Boost - Prostate Cancer, Brachytherapy | Phase 2 / Phase 3 | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 600 | 2026-03-19 | 2026-07-21 |
| PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer Stereotactic Body Radiotherapy (SBRT) Monotherapy, External Beam Radiotherapy (EBRT) Backbone, High-Dose-Rate Brachytherapy Boost - Prostate Cancer (Adenocarcinoma), Prostate Brachytherapy | Phase 2 / Phase 3 | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 1000 | 2026-03-19 | 2026-07-21 |
| Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC Testosterone cypionate (Tc), ADT with Luteinizing hormone-releasing hormone (LHRH) analog, PSMA-617 - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2026-03-03 | 2026-05-15 |
| Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 700 | 2026-02-16 | 2026-09-18 |
| TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Tulmimetostat, Darolutamide, Abiraterone - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 181 | 2026-01-13 | 2026-09-29 |
| Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. N-803 (IL-15 Superagonist), ETBX-071 (PSA-based Oncolytic Virus), M-CENK (Activated NK Cells) - High-risk Prostate Cancer | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2025-12-01 | 2026-05-05 | |
| CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer Androgen Deprivation Therapy (ADT), Docetaxel, PARP Inhibitors and Other Systemic Agents - Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma) | Phase 2 | Not yet recruiting | Fudan University | 112 | 2025-11-30 | 2025-12-08 |
Showing 20 of 87. Sign in to see all of them.
Prostatic Neoplasms (66) · Neoplasm Metastasis (4) · Adenocarcinoma (2) · Breast Neoplasms (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Genital Neoplasms, Male (1) · Lymphatic Metastasis (1) · Prostatic Diseases (1) · Radiation Injuries (1) · Triple Negative Breast Neoplasms (1) · Urogenital Neoplasms (1)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (5) · Fudan University (4) · German Oncology Center, Cyprus (3) · Affidea Nu-med Center of Oncological DIagnostics and Therapy (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · M.D. Anderson Cancer Center (2) · Novartis Pharmaceuticals (2) · OHSU Knight Cancer Institute (2) · University of Chicago (2) · University of Nebraska (2) · University of Utah (2) · University of Washington (2) · baotai Liang (2) · Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD (1) · Alliance for Clinical Trials in Oncology (1)
United States (45) · China (20) · Spain (4) · Australia (3) · Canada (3) · Cyprus (3) · Italy (3) · South Korea (3) · Brazil (2) · France (2) · India (2) · Norway (2) · Poland (2) · Switzerland (2) · United Kingdom (2)
Andrew McDonald, MD (2) · Abhinav Sidana, MD (1) · Abhishek Solanki, MD MS (1) · Adel Mandl (1) · Amado J Zurita Saavedra (1) · Amar Kishan, MD (1) · Angela Y Jia, MD, PhD (1) · Aurelie Garant, MD (1) · Barbara A Jereczek-Fossa, Prof (1) · Benjamin J Rich, MD (1) · Benjamin Maughan, MD (1) · Benjamin Teply (1) · Bo Dai, MD (1)
PMID 40645505, PMID 18407435, PMID 18990168, PMID 22452894, PMID 22747660, PMID 26718929, PMID 26719232, PMID 27068431, PMID 28300506, PMID 28578639, PMID 29240541, PMID 29384722, PMID 29529169, PMID 29723398, PMID 29740894, PMID 30355464, PMID 31500605, PMID 31560068, PMID 32398040, PMID 32651467, PMID 32994091, PMID 33270906, PMID 33386290, PMID 33599706, PMID 34757812, PMID 34953525, PMID 34961659, PMID 35273377, PMID 35671327, PMID 35715340, PMID 36055231, PMID 36059000, PMID 36435336, PMID 36934894, PMID 37142371, PMID 37754491, PMID 37821242, PMID 37973477, PMID 38421252, PMID 38796422, PMID 38824003, PMID 39036382, PMID 39293393, PMID 39643549, PMID 39751962, PMID 39857987, PMID 40177596, PMID 40339593, PMID 40372727, PMID 40387589
2004 (1), 2025 (1), I01CX002277 (1), P30CA033572 (1), P30CA060553 (1), P30CA072720 (1), P50CA097186 (1), R21CA259808 (1), U01CA257638 (1), U10CA031946 (1), U10CA180820 (1), UM1CA186691 (1)